GERMANY – MIG-Fonds 5 invests EUR 27m in Antisense Pharma

Antisense Pharma is the lead investment of MIG fonds 5, which has a placement volume of EUR 70m. The capital will be used to to foster its lead compound towards approval, with preparations for the last clinical trial phase under way. This investment represents one of the biggest VC deals in the biology sector within the last years.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH